ArticleMycopathologia2023
First Terbinafine-Resistant Trichophyton indotineae Isolates with Phe
Article in Mycopathologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Pooled it
- Emerging Terbinafine Resistant Trichophyton Dermatophytosis, Testing Options and Alternative Treatments: A Systematic Review.The Australasian journal of dermatology · 2025Pooled it
- Pooled it
- Mapping the Global Spread of T. indotineae: An Update on Antifungal Resistance, Mutations, and Strategies for Effective Management.Mycopathologia · 2024Pooled it
- Deciphering the genomic landscape ofMicrobial genomics · 2026Article
- Hemolytic and Co-Hemolytic Activity of Trichophyton indotineae and Related Dermatophytes Isolated from Chronic and Recalcitrant Infections.Mycopathologia · 2026Article
- Clinical and Mycological Profiles of Chronic and Recalcitrant Dermatophytosis: Türkiye, 2022-2024.Mycopathologia · 2026Article
- Evaluation of Clinical Studies of Patients With Dermatophyte Infections Caused by Trichophyton indotineae: Treatment Response and Resistance to Antifungal Medications.Dermatology practical & conceptual · 2025Review
- Dermatophytoses Caused byJournal of fungi (Basel, Switzerland) · 2025Article
- Autochthonous transmission ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Antimicrobial Photodynamic Therapy for Superficial, Skin, and Mucosal Fungal Infections: An Update.Microorganisms · 2025Review
- Treatment and diagnostic challenges associated with the novel and rapidly emerging antifungal-resistant dermatophyte,Journal of clinical microbiology · 2025Review
- Expanding the prevalence ofJournal of medical microbiology · 2025Review
- qPCR-Based Molecular Detection of Trichophyton indotineae by Targeting Divergent Sequences.Mycopathologia · 2025Article
- Cutaneous Infections Caused byJournal of clinical medicine · 2025Review
- Dermatophytes: Update on Clinical Epidemiology and Treatment.Mycopathologia · 2024Review
- Article
- Terbinafine Resistance inJournal of clinical medicine · 2024Article
- The Brief Case: A case of tinea corporis caused by drug-resistantJournal of clinical microbiology · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections of the skin, nails, and hair caused by dermatophyte species continue to be a worldwide concern. The increase in terbinafine-resistant superficial dermatophytosis has become a major concern over the last decade. In this report, we presented two cases of infection with terbinafine-resistant Trichophyton indotineae, the first diagnosis of this species in Turkey. One patient exhibited erythematous pruritic patches and plaques in the inguinal and gluteal regions, while the other patient showed annular erythematous scaly plaques in the bilateral posterior thigh and gluteal regions. One patient harbored a CD36 mutation. Both strains harbored the same amino acid substitution in the squalene epoxidase gene, whereas one isolate had another unknown mutation. Clinical improvement was observed with resveratrol treatment in the patient with the CD36 mutation but not in the other patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.